## **Bernard Tawfik**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4492858/publications.pdf

Version: 2024-02-01

1306789 940134 26 268 7 16 citations g-index h-index papers 26 26 26 595 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of Clinical Oncology, 2021, 39, 2539-2551.	0.8	78
2	Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Annals of Hematology, 2014, 93, 47-55.	0.8	54
3	Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). Journal of Geriatric Oncology, 2016, 7, 24-31.	0.5	48
4	The neutrophil to albumin ratio as a predictor of pathological complete response in rectal cancer patients following neoadjuvant chemoradiation. Anti-Cancer Drugs, 2016, 27, 879-883.	0.7	32
5	House Officer–Driven Reduction in Laboratory Utilization. Southern Medical Journal, 2016, 109, 5-10.	0.3	10
6	Reducing Wait Time Between Admission and Chemotherapy Initiation. Journal of Oncology Practice, 2018, 14, e316-e323.	2.5	8
7	Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia. Supportive Care in Cancer, 2019, 27, 2877-2884.	1.0	7
8	Utility and proposed algorithm of CSF flow cytometry in hematologic malignancies. Annals of Hematology, 2018, 97, 1707-1716.	0.8	6
9	Developing a survivorship care plan (SCP) delivery process for patients and primary care providers serving poor, rural, and minority patients with cancer. Supportive Care in Cancer, 2021, 29, 5021-5028.	1.0	6
10	Pharmacist-Driven Oral Oncolytic Medication Education and Consent. JCO Oncology Practice, 2020, 16, e1209-e1215.	1.4	4
11	Improving Outpatient Infusion Clinic Wait Times at a Comprehensive Cancer Center. JCO Oncology Practice, 2021, 17, OP.21.00118.	1.4	3
12	Reply to T. Shimoi et al and Y. Shimanuki et al. Journal of Clinical Oncology, 2021, 39, JCO.21.01905.	0.8	3
13	Ischemic stroke in a patient with moderate to severe inherited factor VII deficiency. Transfusion and Apheresis Science, 2016, 55, 364-367.	0.5	2
14	The Novel Protease-Activated Receptor 1 Antagonist Vorapaxar as a Treatment for Thrombosis in Afibrinogenemia. Seminars in Thrombosis and Hemostasis, 2018, 44, 404-406.	1.5	2
15	Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC) Journal of Clinical Oncology, 2017, 35, TPS6098-TPS6098.	0.8	2
16	Re-induction therapy in adult patients with acute myeloid leukemia with â‰ <b>2</b> 0 % blasts: A retrospective cohort study. Leukemia Research, 2021, 111, 106731.	0.4	2
17	Costs of treatment change following first-line somatostatin analog monotherapy among patients with neuroendocrine tumors. Journal of Medical Economics, 2021, 24, 1337-1345.	1.0	1
18	The neutrophil to albumin ratio as predictor of pCR in rectal cancer patients following neoadjuvant chemoradiation Journal of Clinical Oncology, 2016, 34, e15139-e15139.	0.8	0

#	Article	IF	CITATIONS
19	Retrospective analysis of nadir bone marrow biopsies in predicting need for re-induction therapy in adult acute myeloid leukemia Journal of Clinical Oncology, 2016, 34, e18509-e18509.	0.8	0
20	Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML) Journal of Clinical Oncology, 2017, 35, 10043-10043.	0.8	0
21	Effectiveness of biomarker surveillance after treatment in locoregional breast cancer Journal of Clinical Oncology, 2018, 36, e12608-e12608.	0.8	0
22	Is there a benefit of re-induction therapy in adult patients with AML with <20% blasts?. Journal of Clinical Oncology, 2018, 36, 7021-7021.	0.8	0
23	Rates of hepatitis b screening and prophylactic treatment before immunosuppressive therapy in hematological malignancies Journal of Clinical Oncology, 2018, 36, e18845-e18845.	0.8	0
24	Implementation of algorithm to guide CSF flow cytometry testing in hematological malignancies Journal of Clinical Oncology, 2018, 36, e18792-e18792.	0.8	0
25	Streamlining survivorship care plan (SCP) creation and delivery to primary care providers in poor, rural, and minority patients Journal of Clinical Oncology, 2020, 38, e24181-e24181.	0.8	0
26	Patient, provider, and nurse preferences of patient reported outcomes (PRO) and side effect management during cancer treatment of underrepresented racial and ethnic minority groups, rural and economically disadvantaged patients: a mixed methods study. Cancer Causes and Control, 0, , .	0.8	0